© 2000 by European Society of Cardiology
Effects of intravenous amiodarone on ventricular refractoriness, intraventricular conduction, and ventricular tachycardia induction
akowski
skiska
YskiDepartment of Cardiology, Postgraduate Medical School, Grochowski Hospital Warsaw, Poland
AIMS: Intravenous amiodarone has recently emerged as an important drug for the acute treatment of ventricular tachyarrhythmias. However, electrophysiological actions and the efficacy of the drug in the suppression of ventricular tachycardia inducibility have not yet been fully established. The present study was designed to address these issues.
METHODS AND RESULTS: The study group consisted of 18 patients (all males, mean age 75±14 years), who underwent electrophysiological study due to a history of sustained ventricular tachyarrhythmia or syncope with non-sustained ventricular tachycardia detected on ambulatory ECG monitoring. The effects of 5 mg . kg–1or 10 mg . kg–1of intravenous amiodarone on (1) ventricular refractoriness (QTc interval, right ventricular effective refractory period and monophasic action potential duration), (2) intraventricular conduction (paced-QRS and signal-averaged QRS duration), and (3) ventricular tachycardia inducibility, were examined. The drug had no significant effect on ventricular refractoriness. However, a relatively small but significant slowing of intraventricular conduction was seen (paced-QRS duration: 182±27 ms vs 191±28 ms, P< 0·0007; 183±32 ms vs 195±33 ms, P< 0·0007; and 177±21 ms vs 192±24 ms, P< 0·003, at the cycle lengths of 600, 500 and 400 ms, respectively). This effect was more evident during extrasystolic beats than during stable pacing (for example, at the cycle length of 600 ms, the magnitude of amiodarone-induced lengthening of QRS duration was 23·9±17·6 ms vs 9·7±7·2 ms, P< 0·009, respectively). Intravenous amiodarone did not prevent induction of sustained ventricular tachycardia in any of five patients inducible at baseline. Of six patients with non-sustained ventricular tachycardia, five had sustained ventricular tachycardia or fibrillation induced after amiodarone infusion.
CONCLUSION: Intravenous amiodarone does not prolong ventricular refractoriness, slows intraventricular conduction and may facilitate inducibility of sustained ventricular arrhythmias.
Key Words: Intravenous amiodarone, refractoriness, intraventricular conduction
Correspondence: Piotr Ku
akowski, MD, Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Grenadierów 51/59, 04-073 Warszawa, Poland.
[1] Kowey PR, Levine JH, Herre JM, et al. Randomised, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995; 92: 3255–3263.
[2] Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with lifethreatening ventricular tachyarrhythmias. Circulation 1995; 92: 3264–3272.
[3] Levine JH, Massumi A, Scheinman M, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996; 27: 67–75.[Abstract]
[4] Gomes JAC, Kanf PS, Hariman RJ, El-Sherif N, Lyons J. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J 1984; 107: 214–221.[CrossRef][Web of Science][Medline]
[5] Singh BN, Nademanee K, Kannan R, Ikeda N. The clinical results of amiodarone in cardiac arrhythmias: optimal dosing. PACE 1984; 7: 109–124.
[6] Morady F, DiCarlo LA, Krol RB, Baerman JM, Buitleir de M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 1986; 7: 148.[Abstract]
[7] Kulakowski P, Bashir Y, Heald S, et al. Effects of procainamide on the signal-averaged electrocardiogram in relation to the results of programmed ventricular stimulation in patients with sustained monomorphic ventricular tachycardia. J Am Coll Cardiol 1993; 21: 1428–1439.[Abstract]
[8] Borbola J and Denes P. Oral amiodarone loading therapy. 1. The effect on signal-averaged electrocardiographic recordings and on the QTc in patients with ventricular tachyarrhythmias. Am Heart J 1988; 115: 1202–1208.[CrossRef][Web of Science][Medline]
[9] Du X-J, Murray DE, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995; 91: 462–470.
[10] Kojima S, Wu ST, Wikman-Coffelt J, Parmley WW. Acute amiodarone terminates ventricular fibrillation by modifying cellular Ca++ homeostasis in isolated perfused rat hearts. J Pharm Exp Ther 1995; 275: 254–262.
[11] Mayuga RD and Singer DH. Effects of intravenous amiodarone on electrical dispersion in normal and ischaemic tissues and on arrhythmia inducibility: monophasic action potential studies. Cardiovasc Res 1992; 26: 571–579.
[12] Gough WB, Zeiler RH, Barecca P, et al. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol 1982; 4: 375–380.[Web of Science][Medline]
[13] Gallik DM, Meissner MD, Communale M, Singer I, Hanin L. Favorable hemodynamic effects of Amio-AqueousR, a new formulation of intravenous amiodarone (Abstr). Circulation 1997; 96: 1–383.
[14] Hohnloser SH, Meinertz T, Demmbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone. Results of a prospective placebo-controlled study. Am Heart J 1991; 121: 89–95.[CrossRef][Web of Science][Medline]
[15] Kowey PR, Marinchak RA, Rials SJ, Filart RA. Intravenous amiodarone. J Am Coll Cardiol 1997; 29: 1190–1198.[Abstract]
[16] Venkatesh N, Somani P, Bersohn M, et al. Electropharmacology of amiodarone: absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986; 112: 916–922.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||